Catalog No.
PHK66101
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human CDK12 (Ser717-Gly1054).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
CrkRS, CRK7, Cell division protein kinase 12, KIAA0904, Cyclin-dependent kinase 12, CDC2-related protein kinase 7, CRKRS, CDK12, hCDK12, Cell division cycle 2-related protein kinase 7, Cdc2-related kinase, arginine/serine-rich
Purification
Purified by antigen affinity column.
Accession
Q9NYV4
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer., PMID:39806366
Combined Molecular Subclass and Immune Phenotype Correlate to Atezolizumab Plus Radiation Therapy Response in Invasive Bladder Cancer: BPT-ART Phase 2 Study., PMID:39755215
Quest for discovering novel CDK12 inhibitor., PMID:39697035
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial., PMID:39293514
Acidity-Actuated Polymer/Calcium Phosphate Hybrid Nanomotor (PCaPmotor) for Penetrating Drug Delivery and Synergistic Anticancer Immunotherapy., PMID:39186062
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group., PMID:38894867
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial., PMID:38787530
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis., PMID:38341460
Fertility-Sparing Surgery and Adjuvant Chemotherapy with Trastuzumab Result in Complete Remission in a Young Woman with Rare Primary Mucinous Ovarian Cancer due to ERBB2 Co-amplification with CDK12 and Chromosome 11q13.3 Amplicon: A Case Report and Literature Review., PMID:38216775
Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo., PMID:38061230
Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial., PMID:37325934
An Overview of CDK Enzyme Inhibitors in Cancer Therapy., PMID:36959160
Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers., PMID:36145262
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study., PMID:34844975
Profiling of 520 Candidate Genes in 50 Surgically Treated Chinese Small Cell Lung Cancer Patients., PMID:34168983
CDK inhibitors in cancer therapy, an overview of recent development., PMID:34094661
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors., PMID:33473169
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations., PMID:33433743
Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens., PMID:33298767
Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets., PMID:33116896
NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer., PMID:33058520
CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer., PMID:32941949
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment., PMID:32778095
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma., PMID:32060401
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling., PMID:31468695
Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide., PMID:30587403
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer., PMID:29906450
Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1., PMID:26986210
Phosphorylation of targeting protein for Xenopus kinesin-like protein 2 (TPX2) at threonine 72 in spindle assembly., PMID:25688093
Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration., PMID:22298767
Molecular cloning and characterisation of p15(CDK-BP), a novel CDK-binding protein., PMID:12007796
CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles., PMID:11683387
For research use only. Not for human or drug use.
